- Senate passes Drug Quality and Security Act
- FDA approves Plan B One-Step OTC switch
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- FDA approves liquid form of enalapril to treat BP in children, adults
- Former CMS, FDA chief McClellan delivers keynote at Cardinal Health RBC
BOCA RATON, Fla. Lexington International has announced the launch of its the HairMax LaserComb to more than 9,000 dermatologists in the United States.
The HairMax LaserComb is the first device of its kind to be cleared for marketing by the FDA for certain types of male Androgenetic Alopecia (male pattern baldness). It is available without a prescription.
The medical launch campaign originated with the creation of a Web site aimed specifically at physicians and health care professionals. The site, www.hairmax.com, provides information on the clinical indications and uses of the HairMax LaserComb.
Following completion of the Web site, the manufacturer began a direct mail program announcing the availability of the device to dermatologists. The mailer contained information on the FDA clearance of the HairMax LaserComb, which was supported by a controlled double-blinded study.
The next phase of the campaign will involve providing in-house support to medical professionals via Lexington’s Professional Services Department and utilizing a combination of physician directed journal advertisements, and other direct mail programs.
Future plans for the campaign include Lexington’s planned exhibition at the American Academy of Dermatology Meeting in February 2008, as well as future meetings directed at medical professionals.